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Sininary Plasma parathyroid hormone related-protein (PTHrP) may inhibit the calium-lowering effect of
bisphosphonate therapy. In this prospective study we examined the relationship between plasma PTHrP levels,
renal tubular markers of calcium reabsorption, and the effectiveness of intravenous bisphosphonate therapy
(IVBPT) in lowering serum calcium in patients with hypercacaemia of malignancy (HM), with and without
bone metastases. Thirty-five symptomatic hypercalcaemic patients (17 without and 18 with bone metastases)
were treated with IVBPT (pamidronate 30-60 mg or BM21.0955 2-6 mg). Normocalaemia was achieved in
24,135 (71%) patients with a mean fall in serum calcium of 0.85 mmol 1` (range 0.11-1.93, P<0.001). In the
35 patients studied, serum calcium levels reached a nadir between days 3 and 7, and this was accompanied by
a small but significant reduction in plasma PTHrP levels (median reduction 0.77 pmol 1-', P = 0.007). Patients
who responded to bisphosphonate therapy by becoming normocalaemic had significntly lower basal plasma
PTHrP levels, mean 4.06 vs 8.2 pmol 1- (P<0.04). A significant reduction in urinary calcium excretion was
seen (mean 106pmol 1-', P<0.02) in patients with bone metastases, and urinary cAMP (mean 170 mmol 1',
P<0.01) fell in all patients. Patients without demonstrable bone metastases had significantly higher plasma
PTHrP levels (P< 0.002), required more doses of IVBPT, and had a poorer reduction in serum calcium
compared with patients with bone metastases, only one of whom required more than one dose. We conclude
that circulating PTHrP has an important role in increasing renal tubular reabsorption ofcalcium in HM, thus
reducing the effectiveness of bisphosphonate therapy, particularly in patients with humoral HM and no bone
metastases.
Parathyroid hormone-related protein has been localised in a
wide range of solid tumours, as well as fetal and normal
adult tissues (Danks et al., 1989; Kramer et al., 1991;
Moseley et al., 1991). Increased concentrations of plasma
PTHrP in hypercalcaemia of malignancy (HM) have been
found in up to 88% ofpatients (Grill et al., 1991; Ratcliffe et
al., 1992), and there is overwhelming evidence that tumour-
derived PTHrP is the major hypercalcaemic factor in this
paraneoplastic syndrome (Martin et al., 1989). PTHrP occurs
in three isoforms of 139, 141 and 173 amino acids and shares
70% homology with parathyroid hormone (PTH) at their
extreme amino termini, enabling PTHrP to interact with
classical PTH receptors in bone and kidney, which results in
activation of adenylate cyclase (Juppner et al., 1988). PTHrP
has similar bioactivity to PTH both in vivo and in vitro: when
infused in animal studies it produces hypercalcaemia and
increases bone resorption, renal tubular reabsorption of cal-
cium and nephrogenous cAMP, while reducing renal tubular
reabsorption of phosphate (Martin et al., 1989). In patients
with solid tumours there is evidence that circulating PTHrP
contributes to the hypercalcaemia in patients with bone
metastases as well as those with no bone involvement (Grill
et al., 1991). The treatment of choice for patients presenting
with hypercalcaemia of malignancy is intravenous bisphos-
phonate therapy (Thiebald et al., 1986; Ralston et al., 1987,
1989). Bisphosphonates are stable pyrophosphate analogues
which bind to hydroxyapatite in the bone matrix, and inhibit
osteoclast recruitment and function. Pamidronate (3-amino-
1-hydroxypropyl-idene-l,I-bisphosphonate) is a second-gen-
eration drug which is a potent inhibitor of osteoclastic bone
resorption (Body et al., 1986). Initial studies have shown that
plasma PTHrP levels are unaffected by treatment (Grill et al.,
1992; Blind et al., 1993; Body et al., 1993). These studies also
indicated that the response to intravenous bisphosphonate
therapy (IVBPT) is influenced by the initial plasma PTHrP
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concentration, with patients with the highest levels of plasma
PTHrP showing the poorest response (Blind et al., 1993;
Body et al., 1993). Correlations between initial plasma
PTHrP concentrations and renal tubular handling of phos-
phate (Gurney et al., 1993) and calcium (Body et al., 1993)
suggested that the renal action of PTHrP is responsible for
the poor response to IVBPT. The aim of this study was to
compare plasma PTHrP concentrations, renal tubular
markers of calcium reabsorption, and the effectiveness of
IVBPT in lowering serum calcium in patients with hypercal-
caemia of malignancy and bone metastases and in a similar
group in whom the mechanism of the hypercalcaemia was
predominantly humoral.
Patets and methods
Patients
Thirty-five patients with HM were collected prospectively to
study the effects of intravenous bisphosphonate therapy in a
routine clinical setting. Any patient noted to have received
previous or concurrent treatment affecting calcium meta-
bolism was excluded, i.e. radiotherapy or chemotherapy
within an 8 week period, or any previous bisphosphonate
therapy. Hypercalcaemia was defined as a serum calcium of
greater than 2.6 mmol 1', when adjusted for the serum
albumin (Gardner et al., 1981). The sites of the primary
tumours were breast (10), lung (8), female genitourinary
tract (6), haematological malignancies (3), head and neck
squamous cancers (3), metastatic adenocarcinoma assumed
to be derived from pancreas (2), bladder (1) and disseminated
malignancy from an unknown primary (2). Two patients
receiving pamidronate died during the course of the study.
All patients had plain radiographs, and all patients desig-
nated as not having bone metastases had a negative
radioisotope bone scan. Prior to the institution of bisphos-
phonate therapy, all patients were rehydrated for a minimum
period of 24 h (maximum 48 h), using between 4 and 91 of
0.9% sodium chloride.
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Methods
Thirty-three patients received intravenous pamidronate in
doses chosen by the clinician in charge [30 mg (n = 6), 45 mg
(n= 7) or 60mg (n= 20)], while two received a third-
generation bisphosphonate, BM.210955 (2 and 6 mg), in each
case according to the magnitude of the initial serum calcium
level. If the serum calcium had not fallen below 3.0 mmol 1-
by day 4, a second dose of IVBPT of 30 mg (n = 3), 45 mg
(n = 4) and 60mg (n = 3) was given up to a maximum of
120 mg of pamidronate per patient.
All baseline blood samples were collected following the
rehydration period, immediately before bisphosphonate
therapy was commenced. Venous blood for assay of plasma
PTHrP was collected in the presence of EDTA and 2,000 IU
of apoprotinin and separated within 15 min. Plasma PTHrP
1-86 was assayed by an established two-site immunoradio-
metric assay (IRMA) with a detection limit of 0.23 pmol 1-1
(Ratcliffe et al., 1991). PTHrP 1-86 levels in normocacaemic
controls are <0.23pmoll-' (Ratcliffe et al., 1991). Intact
serum PTH 1-84 was measured by a two-site IRMA
(Nicholls Institute) and levels less than 1.5 pmol 1' were
considered suppressed or subnormal. Urine was collected
between the hours of 10.00 and 12.00. Calcium excretion
(CaE) was caculated by dividing urinary calcium by urinary
creatinine and multiplying by the serum creatinine and was
plotted against the serum calcium to assess renal tubular
reabsorption of calcium (Peacock et al., 1969). Urine cAMP
(UcAMP) was measured using a commercially available kit
(Amersham International), which uses a radiation scintilla-
tion proximity assay without acetylation. The upper limit of
normal as determined in healthy volunteers was 65pmol 1'
[expressed as a function of glomerular filtration (GF)]. Levels
of all analytes (calcium, PTHrP, calcium excretion, UcAMP)
were measured daily until the lowest serum calcium was
achieved (days 3-7).
Statistical analysis was by the Wilcoxon rank test, paired
two-tail t-test, and Spearman's correlation coefficient where
appropriate.
Results
A comparison of the biochemical parameters in the 18
patients with bone metastases and 17 without bone metas-
tases is shown in Table I.
Initial serum calcium levels were not significantly different
between the two groups studied. Normocakaemia was
achieved in 24/35 (71%) patients and the mean fall in serum
calcium was 0.85mmoll1 (range 0.11-1.93, P<0.001).
Serum calcium was normalised in 17/18 (94%) patients with
bone metastases (BM), but in only 9/17 (53%) with humoral
HM (Figure 1). One patient with BM and 8/17 patients with
humoral HM required two doses of IVBPT. All nine patients
who remained hypercalcaemic following therapy became
asymptomatic.
Of the 35 patients with HM studied, 34 (97%) had
elevated plasma PTHrP levels. Basal PTHrP was significantly
higher in patients without overt BM (P<0.05). Follow-
ing IVBPT there was a small but significant decrease in
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Table I Biochemical findings in patients with bone metastases and humoral hypercalaemia
No bone
Bone netastases metastases Significance
(n = 18) (n = 17) p
Serum calcium (mmol I')
Pretreatment Mean 3.46 3.51 NS
Range 2.81-4.81 2.81-4.86
Ref. range 2.20-2.60
Nadir Mean 2.51 2.69 NS
Range 2.34-2.88 2.39-3.27
Fall Mean 0.88 0.86 NS
Range 0.14-1.93 0.38-1.84
PTH I -84 (pmol l-')
Pretreatment Mean < 1.5 < 1.5 NS
PTHrP 1-86 (pmol l)
Pretreatment Median 1.2 *7.8 *<0.002
Range <0.23-14.7 0.46-17.8
Ref. range <0.23
Post-treatment Median 1.045 *3.8 *<0.02
Range <0.23-13.4 0.23-15.69
Median fall 0.2 1.3 *<0.01
Calcium excretion (junol I 'GF)
Pretreatment Median 232 176
Range 24-788 30-380
Post-treatment Median 85 142
Median fall Range 13-342 21-284
Urinary cyclic AMP (nmol 1' GF) *13 <0.02
Pretreatment
Median 86 158
Range 18-2209 54-774
Post-treatment Ref. range <65
Median 71 88
Range 18-610 45-338
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plasma PTHrP in the 35 patients (mean fall 0.77 pmol 1-',
P<0.007). The fall was more marked in patients with
humoral HM (median 1.3 pmol 1', P<0.007), than in those
with BM (mean 0.2 pmol 1', NS) (Figure 1). Initial plasma
PTHrP levels in all patients did not correlate with either the
magnitude of fall or nadir of serum calcium, but plasma
PTHrP levels were higher in the patients who failed to res-
pond to treatment, mean 8.2 vs 4.06 pmol 1' (P<0.04).
Basal urine cAMP, serum creatinine and calcium excretion
all failed to predict the response to bisphosphonate therapy.
Urinary reabsorption of calcium was initially increased in
60% of patients with BM and 86% of patients without BM.
Calcium excretion was initially higher in patients with BM,
and the median fall following IVBPT was also significantly
higher (P<0.04, P<0.02, Table I). Inxeased renal tubular
reabsorption of calcium prior to IVBPT was associated with
a poorer response to bisphosphonates, but the level of in-
creased reabsorption did not predict the magnitude of res-
ponse. There was also a significnt fall in UcAMP in the
patients overall following IVBPT (P<0.01) but no
signiicant difference between the two groups (Table I).
Eiseassiom
There were significant differences in the effectiveness of
IVBPT and the biochemical responses in patients with and
without bone metastases, despite the initial serum calcium
concentrations being similar in the two groups. Serum cal-
cium fell significantly following either a single or repeated
infusion of bisphosphonate and was normalised in 71% of
patients overall, a typical response rate in such patients
(Dodwell et al., 1991). However, a higher proportion of
patients with humoral hypercacaemia required a second
treatment of IVBPT (47% vs 6%), and the proportion
achieving normocacaemia was lower (53% vs 94%), a
finding previously noted by others (Dodwell et al., 1991).
Plsma PTHrP 1-86 measured by two-site IRMA was higher
before treatment in humoral HM, confirming earlier studies
which measured PTHrP 50-69 and 1-74 (Burtis et al., 1990;
Dodwell et al., 1991). Although several earlier studies found
no change in plasma PTHrP levels in patients with hypercal-
caemia of malignancy following IVBPT (Grill et al., 1992;
Blind et al., 1993; Body et al., 1993; Gurney et al., 1993), we
have found a small fall in plasma PTHrP which was
significant only in patients with humoral HM. The ex-
planation for this apparent decline in plasma PTHrP during
IVBPT treatment is unclear. The PTHrP IRMA used in this
study has been extensively validated in clinical studies and
measures increased PTHrP 1-86 levels in approximately
90% ofpatients with hypercakcemia ofmalignancy (Ratcliffe
et al., 1991, 1992). Patients were fully rehydrated before
therapy, and it is possible that treatment was accompanied
by changes in the distribution, metabolism or even secretion
of PTHrP. In vitro studies using Leydig tumour cells have
shown that high extracellular calcium may increase secretion
of PTHrP (Rizzoli et al., 1989), but there is no direct
evidence that calcium regulates tumour secretion of PTHrP.
The decrease found in urinary cAMP excretion foliowing
treatment could in part reflect the obsrved fall in plasma
PTHrP. Biochemical parameters of renal tubular handling of
calcium and phosphate and nephrogenous cAMP provide
indirect indices of the renal actions of tumour-derived PTH-
like bioactivity (Ralston et al., 1987; Gallacher et al., 1992).
These studies and others have provided indirect evidence that
mechanisms involving tumour-derived PTHrP were respon-
sible for hypercalcemia in a high proportion ofpatients with
HM. Our finding that plasma PTHrP levels were higher in
patients with humoral HM is consistent with previous data
which indicated that renal PTH-like activity was also highest
in patients without bone metastases (Ralston et al., 1987) and
may explain why the renal component of HM is unresponsive
to bone-specific agents. The poor response to IVBPT in
patients with humoral malignancy may reflect the high cir-
culating levels of PTHrP in this group, and its effect in
promoting renal reabsorption of calcium. A signant
inverse relationship between plasma PTHrP 50-69 levels and
the response to pamidronate as judged by the time taken to
achieve normocacaemia has been observed (Dodwell et al.,
1991), while elevated plasma PTHrP 53-84 was associated
with a poor response to IVBPT in five out of six patients
(Blind et al., 1993). The biological effects of PTHrP on the
renal tubule appear to be mediated via the PTH receptor,
and a synthetic analogue, Tyr34 bPTH(7-34)NH2, can
inhibit the renal effects of PTH as a result of direct competi-
tion at the PTH-specific receptor site (Horiuchi et al., 1983).
Injection of this analogue in fetal lambs has been shown to
inhibit the renal effects of PTHrP (Davioco et al., 1992).
Antibodies to PTHrP 1-34 have also been shown to lower
serum calcium in a tumour model of hypercakcemia in the
athymic mouse (Kukreja et al., 1988). Although it would be
useful to be able to predict the effective dose or likely res-
ponse of each patient to IVBPT, our data suggest that no
single biochemical or clinical parameter is likely to be
reliable. In the patients studied we found no correlation
between plasma PTHrP and the magnitude offall or nadir of
serum calcium. Despite this, however, basal plasma PTHrP
levels were higher in patients remaining hypercacaemic.
These data are the first to suggest that the response to
therapy may relect the aetiology of the hypercakcemia, i.e.
the presence or abwnce of bone metastases; patients with
humoral hypelaemia and highest plasma PTHrP levels
show the greatest resistance to therapy. Bisphosphonates will
remain the standard treatment for hypercacaemia associated
with bone metastases; however, in future, treatment of
humoral hypercacaemia by bisphosphonates alone may be
inappropriate. Combination therapy with competitive PTH
analogues, or PTHrP monoclonal antibodies, may be
beneficial to prevent the onset of humoral hypercalcemia of
malignancy, and to treat those in whom hypercacaemia is
refractory to current treatments.
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